智翔金泰：斯乐韦米单抗注射液获2岁至18岁以下儿童和青少年疑似狂犬病病毒暴露后的被动免疫适应症临床试验批准

Core Viewpoint - The company has received approval from the National Medical Products Administration for clinical trials of its product, SLEWEMI monoclonal antibody injection, aimed at passive immunity for children and adolescents exposed to suspected rabies virus [1] Group 1 - The clinical trial application for SLEWEMI monoclonal antibody injection has been approved for children aged 2 to 18 years [1] - SLEWEMI monoclonal antibody injection is the world's first bispecific antibody for passive immunity against rabies [1] - The molecular design of SLEWEMI meets the World Health Organization's recommendations for the development of rabies virus antibodies [1]